Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05892744 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression

Study acronym: Re-EMBARC
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv6
  2. Primary completion date: Jun 1, 2026 to Jul 15, 2027
    • Study completion date: Aug 1, 2026 to Jul 15, 2027
    v5
  3. Re-verified, no change to tracked fieldsv4
  4. Start date changed from estimate of Sep 5, 2023 to Sep 30, 2023v3
  5. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Start date: Aug 1, 2023 to Sep 5, 2023
    • Secondary endpoints: details revised at 12 of 12 entries
    • Site details revised
    • Study description shortened, about 5 words
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of the study is to identify brain biomarkers and characteristics that predict individual responses to treatment of major depression with the antidepressant drug sertraline (tradename Zoloft), a common selective serotonin reuptake inhibitor (SSRI) antidepressant. Our central hypothesis is that brain activity and connections jointly measured with functional magnetic resonance imaging (fMRI) and electroencephalogram (EEG) will be able to predict an individual's response to sertraline treatment.
Trial Details
NCT Number NCT05892744
Lead Sponsor University of Texas at Austin
Collaborators: Lehigh University
Conditions
(from sponsor)		 Major Depressive Disorder, Chronic Major Depression, Recurrent
Related terms Depression, Major Depressive Disorder, Recurrence
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov